Dallas, Texas, Oct. 03, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on ...

However, the FDA determined yesterday that the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) ...

Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...

The change will expand access to the diabetes and weight-loss drugs. But it will also complicate the future of compounded ...

The removal of Zepbound and Mounjaro from the regulator’s shortage list could lead to restrictions on pharmacies making ...

BMO Capital Markets analyst Evan Seigerman called it “another positive indication” for Eli Lilly, which is growing market ...

Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, ...

After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has been ...

Telehealth companies and patients are grappling with the potential loss of access to cheaper, alternative versions of Eli ...

Deutsche Bank analyst James Shin maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price target of ...

The FDA says the shortage of tirzepatide injection — a glucagon-like peptide 1 medication used for diabetes and weight loss — ...